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Abstract 
Review on Kidney metanephric adenoma a, with 
data on clinics, and the genes involved. 
Keywords 
Metanephric adenoma of the Kidney; BRAF 
Identity 
Other names 
Embryonal adenoma, Nephrogenic nephroma 
Phylum 
Urinary system: Kidney: Adult: Adenoma: 
Metanephric adenoma 
Note 
A benign renal epithelial tumor resembling 
differentiation toward early embryonic metanephric 
tubules. 
 Figure 1A Metanephric adenomas are typical, 
small, well circumscribed with a fleshy tan cut 
surface (Kelsey McIntyre and Michelle S. Hirsch). 
Figure 1B  Histologically, the tumor cells are small, 
monomorphic and cuboidal. Architecturally, the 
tumors can demonstrate tubular (predominant), 
papillary and glomeruloid growth patterns (courtesy 
Chin-Chen Pan). 
Classification 
Metanephric adenoma belongs to the category of 
Metanephric tumor in the WHO histological 
classification of tumors of the kidney. 
Clinics and pathology 
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Etiology 
Although previously suggested to be derived from 
persistent blastema, metanephric adenoma is 
currently thought to develop from maturation of 
nephroblastoma. 
Epidemiology 
Metanephric adenomas are rare (<1% of renal 
epithelial neoplasms) but occur across a wide range 
of patients, from infants to older individuals.. The 
peak age frequency is 40 to 69 years. There is a 
female predominance (2.3:1). Ten percent of patients 
present with polycythemia. 
Clinics 
Mostly metanephric adenomas are incidentally 
discovered. Some patients present with hematuria 
and abdominal or flank pain. 
Pathology 
Grossly, metanephric adenomas demonstrate a tan to 
fleshy white homogeneous cut surface (Fig. 1A) 
(Grignon et al., 2016). Most tumors are well-
demarcated but lack a true capsule and are typically 
unilateral. Microscopically, the tumor is highly 
cellular and chiefly composed of tightly packed 
primitive tubules; papillary or glomeruloid 
structures may also be seen. The individual tumor 
cells are small, bland and cuboidal with scant 
cytoplasm, and round-to-oval nuclei with smooth 
chromatin, and inconspicuous nucleoli (Fig. 1B). 
Stromal hyalinization, dystrophic calcification and 
psammoma bodies are occasionally seen. 
Metanephric adenomas may resemble 
nephroblastoma or papillary renal cell carcinoma 
microscopically. Mitotic figures are rare or absent; 
necrosis is not seen. Tumor cells are immunoreactive 
for WT1, PAX8 and BRAF, and are typically 
negative for CK7 and AMACR. 
Figure 1B  Histologically, the tumor cells are small, monomorphic and cuboidal.  Architecturally, the tumors 
can demonstrate tubular (predominant), papillary and glomeruloid growth patterns (courtesy Chin-Chen Pan). 
Treatment 
Surgical excision. 
Prognosis 
The vast majority of metanephric adenomas behave 
in a benign fashion. Cases of regional lymph node 
metastasis and sarcomatoid changes have been 
individually reported. 
Cytogenetics 
No consistent cytogenetic abnormalities have been 
identified in metanephric adenoma. The gains of 
chromosomes 7 and 17 noted in papillary renal cell 
carcinoma, as well as the chromosome gains of 1q, 
7q, and 12, and losses of 11p and 16q commonly 
seen in Wilms' tumor have not been detected in 
metanephric adenoma. 
Kidney: Metanephric adenoma 
Atlas Genet Cytogenet Oncol Haematol. 2018; 22(1) 36 
Genes involved and 
proteins 
Approximately 90% of metanephric adenomas 
contain a V600E activating mutation in exon 15 of 
BRAF (Choueiri et al., 2012). BRAF-mutated 
metanephric adenomas stain positive for V600E 
mutation-specific immunohistochemistry (Pinto et 
al., 2015; Udager et al., 2015). BRAF mutations are 
very rare (<1%) or absent in other renal tumor 
subtypes. 
BRAF (v-raf murine sarcoma viral 
oncogene homolog B1) 
Location 
7q34 
Note 
BRAF V600E mutations are found in approximately 
90% of metanephric adenomas. 
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